Kesik Vural, Atas Erman, Korkmazer Nadir, Babacan Oguzhan
Department of Pediatric Oncology, Gulhane Military Medical Academy, Etlik, Ankara, Turkey.
J Cancer Res Ther. 2015 Jul-Sep;11(3):653. doi: 10.4103/0973-1482.138028.
Clofarabine is an effective drug in relapsed leukemia and lymphoma that has some adverse effects which can be fatal like capillary leak syndrome (CLS). Identification and management of CLS is important that may result in mortality. Although prophylactic treatment with steroids may prevent CLS and improve survival, intravenous immunoglobulins are used in the treatment with great success in steroid resistant cases. However, the knowledge about the effects and the dose of intravenous immunoglobulins (IVIG) in pediatric patients is limited. Herein, we reported a patient with relapsed lymphoma who developed CLS successfully and was treated with IVIG.
氯法拉滨是一种用于复发白血病和淋巴瘤的有效药物,它有一些可能致命的不良反应,如毛细血管渗漏综合征(CLS)。识别和处理CLS很重要,因为这可能导致死亡。虽然使用类固醇进行预防性治疗可预防CLS并提高生存率,但静脉注射免疫球蛋白在治疗类固醇抵抗病例中取得了巨大成功。然而,关于静脉注射免疫球蛋白(IVIG)在儿科患者中的作用和剂量的知识有限。在此,我们报告了一名复发淋巴瘤患者,该患者成功发生CLS并接受了IVIG治疗。